Search
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review
Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. Journal of Oncology Pharmacy Practice. 2024;30(4):721-736.
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Garcia-Manero G, McCloskey J, Griffiths E, Lancet Haematology. 2024, e15-e26
Patients’ perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms
Zeidan AM, Perepezko K, Salimi T, et al. Therapeutic Advances in Hematology. 2024;15.
Impact of hypomethylating agent use on hospital and emergency room visits, and predictors of early discontinuation in patients with higher-risk myelodysplastic syndromes
Zeidan AM, Joshi N, Kale H, et al. Clinical Lymphoma, Myeloma & Leukemia. 2022;22(9):670-679.
Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes
Zeidan AM, Tsai JH, Karimi M, et al. Clinical Lymphoma, Myeloma & Leukemia. 2022;22(9):e853-e866.
Injectable hypomethylating agents for management of myelodysplastic syndromes: patients’ perspectives on treatment
Zeidan AM, Jayade S, Schmier J, et al. Clinical Lymphoma, Myeloma & Leukemia. 2022;22(3):e185-e198.
Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective cohort analysis
Joshi N, Kale H, Corman S, et al. Clinical Lymphoma, Myeloma & Leukemia. 2021;21(3):e248-e254
Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis
Corman S, Joshi N, Wert T, et al. Clinical Lymphoma, Myeloma & Leukemia. 2021;21(2):e206-e211.
Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Cheng WY, Satija A, Cheung HC, et al. Hematology. 2021;26(1):261-270.